Novartis AG (NOVN) entered a collaboration with Regenerex LLC, gaining access to stem cell technology that may help kidney transplant patients avoid taking anti-rejection medicine for life. Regenerex, a startup biology company based in Louisville, Kentucky, and Novartis have entered an exclusive global licensing deal and will work together on research, the Basel, Switzerland-based company said in an e-mailed statement today. Regenerex’s technology allowed five of eight kidney transplant patients to stop taking about a dozen pills a day to suppress their immune systems, according to research published last year.
Help employers find you! Check out all the jobs and post your resume.
